Induction in Biological Technology

Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes

... of freshly isolated hepatocytes for studies like induction severely restrict the researcher's choices for ... and accelerating time to market. Standard induction studies, as an example, typically may be ... activities, genotypes and for applications like induction or transport, representing another major ...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

... shows an extended duration of response in an induction and maintenance clinical trial of Crohn's disease ... at week 6. The trial demonstrated that after the induction period 62 percent of patients achieved response ... rance to infliximab. It consists of an open-label induction phase (400 mg of Cimzia(R) sub-cutaneously at ...

ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week

... trial results from more than 430 patients in the induction phase of the PROTECT-1 study in the following ... The innovative trial design includes a 12-week induction phase, during which patients with ... to induce a clinical response or remission. The induction phase of the study is followed by a four-week, ...

Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting

... histone deacetylase inhibitor, followed by CYP1A1 induction and subsequent AFP metabolism into active species ... sequence on the CYP1A1 promoter region, causing induction of CYP1A1 transcription. This enzyme expression ... DNA. This results in phosphorylation of p53 with induction of the p53 downstream target p21Waf1/Cip1 and ...

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

... Injection as a single agent for remission induction treatment for patients sixty years of age or ... a lower rate of response to currently available induction chemotherapy and shorter overall survival due, in ... age and poor performance status tolerate current induction treatments poorly. A 2005 study by Lang et al, ...

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

... AML patients unlikely to benefit from standard induction chemotherapy. Interim results recently presented ... 17 percent, which compares favorably to standard induction chemotherapy. Data on the median duration of ... are not considered candidates for standard induction therapy or decline therapy, resulting in an acute ...

DRC's Metrigraphics Announces Family of Micro-Induction Coils for Implanted and Traditional Medical Applications

... and Transmission and induction Functionality -- Medical Design & ... high volumes of coils per sheet produced. * The induction coils permit passive devices, with power being obtained through induction only when required. This feature eliminates the ...

Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

... with MMX(R) technology, indicated for the induction of remission in patients with active, mild to ... oral formulation of mesalamine indicated for the induction of remission in patients with active, mild to ... ulcerative colitis. LIALDA is indicated for the induction of remission in patients with active, mild ...

Millennium Over-Delivers on 2007 Goals and Financial Guidance

... and dexamethasone (VAD), a commonly used induction therapy prior to SCT. The VELCADE based induction regimen enhanced post SCT outcomes for patients ... and dexamethasone (VcTD), as induction therapy prior to SCT, showed a dramatic fourfold ...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

... study, conducted by Cardium's Tissue Repair Company, entitled Bone induction by AdBMP-2/Collagen Implants, (Schreiber, et al., J Bone Joint Surg, ... study, conducted by Cardium's Tissue Repair Company, entitled Bone induction by AdBMP-2/Collagen Implants, (Schreiber, et al., J Bone Joint Surg, ...

Sunesis Reports Financial Results for the Second Quarter 2009

... diagnosed elderly AML patients who are unlikely to benefit from standard induction chemotherapy. Interim clinical data from this study continue to show that ... A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment ...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

... received 0.25 mg gonadotropin-releasing hormone (GnRH) antagonist until induction of final oocyte maturation by hCG. About 34-36 hours after induction of final oocyte maturation, oocyte pick up followed by IVF or ICSI was ...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

... for both agents and accumulation of the drugs over the three dose induction course (infusions on Days 1, 3, 5). These results suggest that effective ... be exposed to cytotoxic drug levels throughout the first two weeks of induction treatment. In a separate poster presentation, researchers described ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... toxicology and pharmacology studies in animals that demonstrated stable induction of interferon-dependent pathways at doses that led to no adverse findings. ... of the study, dosing in healthy volunteers showed evidence of immune induction starting at 800 mg. Tolerability in healthy volunteers was generally ...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results

... newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy. Schedules A (72 mg/m2 of voreloxin weekly for three weeks) ... A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment ...

New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease

... at baseline had closure of fistulas by Week 26 following short-term induction therapy with CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNFa ... study of CIMZIA(R). In PRECiSE 2, patients received an open-label induction with subcutaneous CIMZIA(R) 400 mg at Weeks 0, 2 and 4. Those who ...

3SBio Inc. Files for SFDA Approval of NuLeusin

... cycle, patients were given daily doses of 7MIU/square meter in the induction phase and daily doses of 3.5MIU/square meter in the maintenance phase. The ... five consecutive days in the first week of each treatment cycle during the induction phase. From the second week onward, during the maintenance phase, patients ...

Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients

... in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects ... observed with every-other-day dosing of ANA773 in monkeys included induction of interferon-alpha and interferon dependent responses at levels that are ...

Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research

... E2B8 and EAAF are sub-micromolar inhibitors of the kinase. Mechanism of induction of Apoptosis by TLK199 (TELINTRA(R)) in Human Leukemia Cell Lines ... a key signaling event in the integrated stress response (ISR), and in induction of multiple genes implicated in ISR. Telik currently has ongoing studies ...

Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans

... Flute(R) presents a safe, effective, convenient and rapid method of sputum induction for patients participating in our veterans' clinical study for lung ... said Connie Dorian, Director of Technical Operations for Biomoda. "Sputum induction with the Lung Flute is safer, less time consuming, more convenient and ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... ANA773 was generally well tolerated with no serious adverse events. Plasma drug levels were proportional to dose, and there was a dose-dependent induction of well-recognized interferon dependent biomarkers. Phase I Clinical Trial in Oncology. In order to focus its resources on ANA598, Anadys ...

Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting

... growth factors and contains the first naturally stabilized, bioactive solution of Wnt proteins and their cofactors, which have been implicated in the induction of new hair follicle formation and growth. The five-month double-blind, placebo-controlled clinical trial was focused on evaluation of safety in ...

Abbott Named One of the Top 10 Companies for Scientists

... their workplace. Abbott has numerous recognition programs for scientists, including management recognition programs, patent/inventor awards and induction into the prestigious Volwiler Society, which was established to recognize the company's most distinguished scientists and engineers. Named for the ...

Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients

... open-label clinical trial was conducted where 424 kidney transplant recipients received Prograf or cyclosporine in combination with MMF, basiliximab induction and corticosteroids . The study reported that the rate for the combined endpoint of biopsy proven acute rejection, graft failure, death and/or lost ...

First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418

... activated in human cancer). GGTase I inhibitors block Rho function in cancer cells and induce a G1 phase cell cycle arrest by a mechanism involving induction of the CDK inhibitors p21waf and p27kip, CDK2 and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce ...

ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program

... a variety of tumor cell types (prostate, lung, ovary, colon, CNS, melanoma, and hematopoietic lineages) by disruption of cell cycle progression and induction of apoptosis with a secondary anti-angiogenic activity as a consequence of the cytoskeletal disruption. The unique activity, novel structure, potent ...

Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy

... the delayed phase of CINV*. Palonosetron 0.075 mg IV is also approved by FDA as a single intravenous dose administered immediately before the induction of anaesthesia for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Palonosetron is ...

Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor

... M. Sebti, Ph.D. from Moffitt. "This small molecule is a highly selective and potent inhibitor of Akt activation, leading to tumor growth arrest and induction of cancer cell death, and results in overcoming chemoresistance," said Dr. Cheng, Professor, Molecular Oncology Department at Moffitt. "Patients ...

Pepscan Achieves First Milestone in Research Collaboration With Genmab

... constrained configuration. These molecules behave as functional mimics of complex protein domains that serve as superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as ...

FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418

... activated in human cancer). GGTase I inhibitors block Rho function in cancer cells and induce a G1 phase cell cycle arrest by a mechanism involving induction of the CDK inhibitors p21waf and p27kip, CDK2 and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce ...

Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes

... for use with Promega's bioluminescent ADME-Tox assays, including the P450-Glo(TM) CYP Assay used to study cytochrome P450 gene induction and inhibition and the GSH-Glo(TM) Glutathione Assay for investigating mechanisms of hepatotoxicity. "Researchers are looking for validated ...

Tigris Pharmaceuticals Files IND Application for GGTI-2418

... activated in human cancer). GGTase I inhibitors block Rho function in cancer cells and induce a G1 phase cell cycle arrest by a mechanism involving induction of the CDK inhibitors p21waf and p27kip, CDK2 and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce ...

BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis

... and/or DR4); MS patients having these genes represent approximately 70 percent of all MS patients. The drug's proposed mechanism of action is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered ...

Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009

... on a supplemental biologics license application (sBLA) submitted on October 2, 2008 for the use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. CTI and Spectrum have a joint venture for the sales, marketing and ...

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

... thrombin-antithrombin complex or TAT (0.01), interleukin 6 or Il-6 (p=0.04), and tissue factor microparticles or TFMP (0.02) during the four-week induction phase of treatment. All decreases in D-dimers, TAT, Il-6, TFMP, and LDH were sustained in the maintenance phase of treatment. The authors ...

FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review

... for progression free survival. About First-Line Consolidation Therapy Consolidation therapy is a treatment given after initial induction therapy and is aimed at improving the quality of the patient response by further diminishing the number of cancer cells with the goal of extending ...

Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting

... The results also support the finding that AEG35156 combination therapy may induce high response rates in AML patients not responding to frontline induction therapy. Updated results on additional patients will be presented at the ASH Annual Meeting. The study's principal investigator, Dr. Aaron D. ...

Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008

... Biologics License Application to the U.S. Food and Drug Administration (FDA) in September for use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma based on First-line Indolent Trial data. -- Announced that CTI has closed ...

Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium

... and profile of the laser treatment itself. The use of wavefront-guided treatments and/or optimized treatments significantly reduce the postoperative induction of spherical aberration, most responsible for night vision symptoms. Therefore, when adequately informed, those individuals with large night time ...

Publication on 'Tregitopes' in Blood Journal of October 2008

... are co-administered with Epi-13. Preliminary in vitro and in vivo studies indicate that the modification of the immune response is due to the induction of natural T reg cells. About EpiVax EpiVax, Inc. is a biotechnology company that is dedicated to merging in vitro immunology research with ...